Literature DB >> 3776689

Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis.

B Lindholm, H E Norbeck.   

Abstract

The effects of continuous ambulatory peritoneal dialysis (CAPD) on serum lipids and lipoproteins over the initial year of therapy were studied in 23 uremic patients. Lipoprotein abnormalities typical for the uremic dyslipoproteinemia were present at the start of CAPD. During the first months of CAPD these abnormalities were accentuated. The concentrations of very low density lipoprotein (VLDL)-cholesterol (CHOL), low density lipoprotein (LDL)-CHOL, serum CHOL and serum triglycerides (TG) increased significantly. However, after one year of CAPD only the VLDL-CHOL and serum CHOL levels remained significantly higher than the baseline values. VLDL-TG, VLDL-CHOL and serum TG, and the changes of these variables over the study period, correlated with the amount of glucose in the dialysates. We conclude that the continuous peritoneal absorption of glucose (100-200 g/24 h) during CAPD contributes to potentially atherogenic changes in serum lipids and lipoproteins. However, some of the changes are transitory, indicating an adaptation to the peritoneal glucose load.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3776689     DOI: 10.1111/j.0954-6820.1986.tb02742.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  9 in total

1.  Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.

Authors:  Yun Li; Qiong-hong Xie; Huai-zhou You; Jing Tian; Chuan-ming Hao; Shan-yan Lin; Tong-ying Zhu
Journal:  Perit Dial Int       Date:  2012-03-01       Impact factor: 1.756

2.  Mononuclear leucocyte function tests in the assessment of the biocompatibility of peritoneal dialysis fluids.

Authors:  H F Brulez; P M ter Wee; S V Snijders; A J Donker; H A Verbrugh
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

3.  A Model To Estimate Glucose Absorption in Peritoneal Dialysis: A Pilot Study.

Authors:  Suman Krishna Kotla; Ashish Saxena; Ramesh Saxena
Journal:  Kidney360       Date:  2020-09-29

Review 4.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

5.  Hyperlipidemia in pediatric patients undergoing peritoneal dialysis.

Authors:  U Querfeld; I B Salusky; P Nelson; J Foley; R N Fine
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

Review 6.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

7.  Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.

Authors:  Alastair J Hutchison; Maggie Gill; J Brian Copley; Lynne Poole; Rosamund J Wilson
Journal:  BMC Nephrol       Date:  2013-02-18       Impact factor: 2.388

8.  The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level.

Authors:  Eiichiro Kanda; Masumi Ai; Mitsuyo Okazaki; Yoshitaka Maeda; Sei Sasaki; Masayuki Yoshida
Journal:  BMC Nephrol       Date:  2013-10-07       Impact factor: 2.388

9.  The value of time-averaged serum high-sensitivity C-reactive protein in prediction of mortality and dropout in peritoneal dialysis patients.

Authors:  Shou-Hsuan Liu; Chao-Yu Chen; Yi-Jung Li; Hsin-Hsu Wu; Chan-Yu Lin; Yung-Chang Chen; Ming-Yang Chang; Hsiang-Hao Hsu; Cheng-Lung Ku; Ya-Chung Tian
Journal:  Ther Clin Risk Manag       Date:  2017-08-16       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.